



Paradoxical uncoupling activity of tetradymol isolated from *Tetradymia glabrata*
by Andrij Holian

A thesis submitted in partial fulfillment . of the requirements for the degree of DOCTOR OF
PHILOSOPHY in Chemistry
Montana State University
© Copyright by Andrij Holian (1975)

Abstract:

Clinical studies on acute toxicity of tetradymol have substantiated previous research in the hepatotoxic activity of tetradymol. Furthermore, studies herein suggest that tetradymol is modifying energy metabolism, "In vitro" studies on whole mitochondria have established tetradymol as an uncoupler of oxidative phosphorylation. Using submitochondrial particles, tetradymol behaved as an ATPase inhibitor. This paradoxical behavior has been used to suggest that tetradymol does not cross over either side of the mitochondrial membrane.

Using both mitochondria and submitochondrial particles, related compounds have been investigated with respect to various parameters of coupled respiration. With the knowledge gained, a stereochemical model of the active site has been proposed.

PARADOXICAL UNCOUPLING ACTIVITY OF TETRADYMOL
ISOLATED FROM TETRADYMIA GLABRATA

by

ANDRIJ HOLIAN

A thesis submitted in partial fulfillment
of the requirements for the degree

of

DOCTOR OF PHILOSOPHY

in

Chemistry

Approved:

Dr. P. W. Jennings
Chairman, Examining Committee

E. W. Anacker
Head, Major Department

Henry L. Parsons
Graduate Dean

MONTANA STATE UNIVERSITY
Bozeman, Montana

December, 1975

ACKNOWLEDGMENTS

The author would like to express his gratitude to the following individuals for their patience, guidance and assistance during the course of this research project.

Dr. P. W. Jennings, Graduate advisor

Dr. J. E. Robbins, Graduate advisor

Dr. W. Hill, Assistance in histology
slide evaluation

Dr. J. Inhelder, Assistance in histology
slide evaluation

Gayle Callis, Preparing histology slides

Dr. G. McFeters, Providing oxygraph

Dr. D. Mathre, Technical assistance

He would like to give special thanks to his wife, Sandra, for assistance in the laboratory and understanding when dark days abounded.

Acknowledgment is also due the National Institute of Health for research funds.

TABLE OF CONTENTS

	page
LIST OF FIGURES	v
LIST OF TABLES	vi
ABSTRACT	ix
INTRODUCTION	1
RESULTS AND DISCUSSION	29
Conclusion	61
EXPERIMENTAL SECTION	65
Reagents	65
Instruments	68
Mice	68
Histology slides	69
Isolation of mitochondria and submitochondrial particles	69
Standard determinations	69
Experiments	71
APPENDIX	
A. Clinical tests	94
B. Structures of Related Compounds	96
LITERATURE CITED	99

LIST OF FIGURES

	page
1. Urea cycle	6
2. Representation of mitochondrion	7
3. Representation of cristae	8
4. Representation of submitochondrial particle	9
5. Electron chain and oxidative phosphorylation	10
6. State 4 respiration vs uncoupler concentration	17
7. Rifampicin and its three metabolites	21
8. Structure of chlordimeform	22
9. p-nitro analog of chlordimeform	23
10. Structure of clofibrate	24
11. Dependence on K^+ concentration	28
12. Effect of tetradymol on state 4 respiration	34
13. Effect of tetradymol on RC and P/O	36
14. Tetradymol uncoupling vs pH	48
15. Tetradymol uncoupling vs protein	51

LIST OF TABLES

	page
1. Relationship of histology to clinical results	4
2. Inhibitors of the mitochondrial ETS	12
3. Various classifications of uncouplers	13
4. Generalized uncoupler characteristics	14
5. Clinical chemistry	29
6. Citrulline production	33
7. Effect of tetradymol on state 4 respiration	35
8. Effect of tetradymol on RC	37
9. Effect of tetradymol on P/O ratios	38
10. Effect of tetradymol on P/O ratios	39
11. Relative uncoupling at 3 sites	40
12a. Reversal of ATPase inhibition	41
12b. Reversal of ATPase inhibition	41
13. Mitochondrial ATPase activity	42
14. Reverse electron flow in mitochondria	42
15. Effect of tetradymol on mitochondria	45
16. Comparison of SDS and tetradymol uncoupling	45
17. Varying K^+ concentration	46
18. Tetradymol uncoupling vs pH	47
19. Tetradymol uncoupling vs protein	49
20a. Effect of BSA	50
20b. Effect of BSA	50
21. Reverse electron flow in submitochondrial particles	53

	page
21. Reverse electron flow in submitochondrial particles	53
22. Submitochondrial ATPase activity	54
23. Effect of tetradymol on submitochondrial oxygen consumption rates	55
24. P/O in submitochondrial particles	56
25. Submitochondrial ATPase activity	57
26. Mitochondrial ATPase activity	58
27. Relative uncoupling ability of tetradymol-like compounds	60
28. Ornithine transcarbamylase activity	73
29. Urea production	73
30. Effect of tetradymol on mitochondrial oxidative phosphorylation	76
31. Mitochondrial P/O	77
32. Mitochondrial reverse electron flow	78
33. Submitochondrial reverse electron flow	79
34. Mitochondrial ATPase	80
35. Submitochondrial ATPase	81
36. Reversal by tetradymol of DCCI inhibited mitochondrial ATPase	82
37. Effect of BSA on tetradymol uncoupling	83
38. Effect of varying K^+ on tetradymol uncoupling	84
39. Effect of varying pH on tetradymol uncoupling	85
40. Effect of varying mitochondrial protein	86
41. Effects on O.D. of a mitochondrial solution	87
42. SDS effect on state 4	87

	page
43. Effect of tetradymol on O_2 uptake with submitochondrial particles	87
44. Uncoupling ability of tetradymol like compounds	89
45. Relative uncoupling at 3 sites	91

Abstract

Clinical studies on acute toxicity of tetradymol have substantiated previous research in the hepatotoxic activity of tetradymol. Furthermore, studies herein suggest that tetradymol is modifying energy metabolism.

"In vitro" studies on whole mitochondria have established tetradymol as an uncoupler of oxidative phosphorylation. Using submitochondrial particles, tetradymol behaved as an ATPase inhibitor. This paradoxical behavior has been used to suggest that tetradymol does not cross over either side of the mitochondrial membrane.

Using both mitochondria and submitochondrial particles, related compounds have been investigated with respect to various parameters of coupled respiration. With the knowledge gained, a stereochemical model of the active site has been proposed.

INTRODUCTION

This study has been directed towards obtaining information as to the toxicity of tetradymol. For a better understanding of the research and implications involved, a number of pertinent subjects will be reviewed and references given for additional information. Initially a brief review of previous work on the project will be presented. For more indepth information the reader is referred to both S. Holian¹ and S. Reeder's² theses.

Tetradymol is a toxic substance isolated from the plant Tetradymia glabrata. Reeder² observed from whole plant feeding experiments with sheep that: 1) feeding 1% of body weight for three days resulted in death; 2) bromsulphalein (BSP) clearance time was greatly lengthened; 3) blood serum ammonia levels were elevated three to six fold in poisoned sheep. The latter two observations led to the conclusion of liver dysfunction.

Autopsies were performed on all sheep that were poisoned. The results are summarized below:³

1. Liver tissue demonstrated panlobular necrosis localized in the centrallobular area.
2. Kidney tissue showed some general congestion and swelling and hyperemia especially in the medulary portion.
3. Varying degrees of congestion were reflected in the lungs with some emphysema and bronchiolar hemorrhage.
4. Cardiac tissue was not greatly different from normal revealing some congestion and a few subepicardial hemorrhages.

It was concluded that the toxic principles were manifested primarily in the liver.

Information obtained from histology studies on mice after being fed purified tetradymol established that only the liver was affected. Tetradymol causes dose dependent centralobular necrosis that is apparent at two hours by swelling of the liver cells and increases in severity up to death (10 hours). The damage can be seen as cytoplasmic vacuolar degeneration, necrosis (complete loss of cell differentiation), and nuclear pyknosis (shrinking of nuclei) and karyorrhexis (swelling and disruption of nuclei).⁴

In addition, it was established that metabolite(s) formed from the metabolism of tetradymol by the liver mixed function oxidase system was more toxic than tetradymol.⁵ Furthermore, it was proposed that tetradymol itself could still be toxic.

To gain further general information on the toxicity of tetradymol a number of clinical serum tests were conducted. The purpose of these tests was to gain additional information concerning organ involvement and to observe altered serum metabolite concentrations that might implicate a possible mode of action of tetradymol "in vivo". A clarification and possible interpretations of those tests that will be important in the discussion will follow. More detail on these following tests and others can be found in the following references.^{6,7,8}

A test related to the BSP clearance time (mentioned earlier) is determination of bilirubin levels. In both cases (BSP and bilirubin) the liver extracts the compounds and excretes them in the bile. Additionally, bilirubin is conjugated before it is excreted.⁹

Two kinds of bilirubin are measured. One is termed direct reacting bilirubin which has been conjugated in the liver with glucuronide. Increases occur commonly in cases of obstructive jaundice, intrahepatic obstruction or hepatocellular damage. Hepatotoxic agents, such as, erythromycin or chlorpromazine, will cause elevations due to intrahepatic obstruction and damage.¹⁰ The other form of bilirubin (which is of greater interest in this research) is termed indirect reacting (unconjugated) bilirubin. This form is bound to serum albumin until extracted by the liver to be conjugated. Elevation of this form is due to either increases of hemolytic anemia or from deficiencies in the liver conjugation processes. An agent, such as, methyltestosterone, will cause this type of damage.¹⁰

The clinical manifestations of liver injury can be related to the histological observations (Table 1).¹⁰ Since tetradymol has been shown (stated earlier) to cause a zonal necrosis, clinical tests could be used to substantiate these findings.

Liver necrosis will produce high levels of serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT). Slight increases of alkaline phosphatase and variable levels of flocculation tests are dependent on different types of necrosis. Jaundice has lower transaminase levels and flocculation tests are low. Cholestasis with accompanied portal inflammation gives high alkaline phosphatase levels; while, without inflammation alkaline phosphatase levels are normal. Agents, such as, sulfonamide will produce various combinations of the above by causing both cytotoxic necrosis and cholestasis.

Table 1
Relationship of Histology to Clinical Results¹⁰

HISTOLOGIC LESION	BIOCHEMICAL ABNORMALITIES			EXAMPLES OF HEPATOTOXIC AGENTS
	SGOT AND SGPT	ALK. PHOS.	THYMOL TURB. AND CEPH. FLOCC.	
I. Cytotoxic Necrosis—Zonal	↑↑↑↑	↑	±	CCl ₄
Necrosis—Diffuse	↑↑↑↑	↑	↑↑	Iproniazid
Fatty Metamorphosis	↑↑	±	±	Tetracycline
II. Cholestatic				
A. With Portal Inflammation	↑↑	↑↑↑↑	—	Erythromycin; Chlorpromazine
B. Without portal inflammation (Bland)	↑↑	±	—	Methyltest.
III. Mixed Mixture of Cytotoxic and Cholestatic	↑ → ↑↑↑↑	↑ → ↑↑↑↑	— → ↑↑	Sulfonamides

Measurement of blood ammonia levels is not a routine clinical test but elevations in blood ammonia have been implicated in a number of different liver dysfunctions; e.g., hepatic coma,^{11,12} Reye's Syndrome,^{13,14} and alcoholic cirrhosis.¹⁵ Hepatic coma can accompany various forms of liver dysfunction as a complication. The exact cause of the coma is not certain but accompanied increases in blood ammonia levels have been suspected. The recently important Reye's Syndrome has, as a symptom, elevated blood ammonia levels. Administration of ammonium salts has been shown to increase blood ammonia and cause death.^{16,17} The cause for the rise in blood ammonia can be due to a number of factors where the urea cycle is concerned. In cases of ammonium salt poisoning, the activity of the urea cycle¹⁸ (figure 1) is not sufficient to assimilate the ammonia into urea. Otherwise some deficiency in the urea cycle could be causing poor assimilation of ammonia. Genetic deficiencies in the urea cycle enzymes have been reported to cause increases in blood ammonia.^{19,20} Lack of ATP has also been suggested as a contributing factor since three ATP's (four high energy bonds) are required for each urea synthesized.²¹

There are a number of methods that have been tried (sometimes successfully) for reducing blood ammonia levels. These methods can be divided into two groups: 1) Administration of glutamic acid with the hope that ammonia will be removed by




Figure 1: Urea cycle

